Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "AI in Biotechnology Market - Global Industry Size, Share, Growth, Trends, Opportunity, and Forecast, 2025-2033" report has been added to ...

The "FDA Regulatory Compliance for Drug and Biotech Products (Nov 12th - Nov 13th, 2025)" training has been added to ResearchAndMarkets.com's offering. Regulatory Compliance is the level of activity ...

Alector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like Parkinson’s and Alzheimer’s diseases, is laying off about half of its staff. The ...

With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the treatment of rheumatoid arthritis. London-based Elevara was founded by ...

Intensity Therapeutics Inc., a clinical-stage biotechnology company based in Shelton, announced this week that its shareholders have approved a reverse stock split. The announcement, made Tuesday in a ...

Alector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like Parkinson's and Alzheimer's diseases, is laying off about half of its staff. The ...

Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as Recursion.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Sara Kenkare-Mitra, the company ...